REGENEREX PHARMA INC. (RGPX) Annual Balance Sheets

Annual · GAAP · USD millions
Access RGPX quarterly Balance Sheets →
Tracking balance sheet results across REGENEREX PHARMA INC. to Mar 31 2020 helps illustrate how Mar 31 2025's financial position has responded to changing business conditions.
Annual Report, GAAP in USD millions
ITEM
(Mar 31 2025)
(Mar 31 2022) (Dec 31 2021) (Dec 31 2020) (Mar 31 2020)
Assets
Cash & cash equivalent0.65
Cash & Short-term Investments0.00
Inventories0.00
Total loans net0.00
Total Current Assets0.65
Equipment/Property/Plant Net0.01
Intangible Assets0.01
Tax Assets, Noncurrent1.58
Total Assets1.26
Liabilities
Accounts Payable0.20
Accrued Liabilities, Current0.84
Short-term Debt2.82
Total Current Liabilities4.92
Long-term debt0.00
Total Long-term Debt0.00
Total Liabilities5.42
Stockholders' Equity
Common Stock Value0.28
Additional Paid In Capital Common Stock3.71
Retained Earnings / Accumulated Deficit-8.14
Defined Benefit Plan and Other5.68
Common Stockholder's Equity-4.16
Total Stockholder's Equity-4.16
Liabilities & Stockholder's Equity1.26
4 historic quarters locked

Sign in to unlock the full REGENEREX PHARMA INC. balance sheet history.

About Regenerex Pharma Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20250331)
  • Filed with the SEC: June 30, 2025
  • Source: ixform10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001472375-25-000070

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License